Estabrook Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Estabrook Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.8K	Hold	69	–	–	﹤0.01%	216
2025 Q4	$31.3K	Hold	69	–	–	﹤0.01%	213
2025 Q3	$27K	Hold	69	–	–	﹤0.01%	222
2025 Q2	$30.7K	Hold	69	–	–	﹤0.01%	213
2025 Q1	$33.5K	Hold	69	–	–	0.01%	203
2024 Q4	$27.8K	Hold	69	–	–	﹤0.01%	221
2024 Q3	$32.1K	Hold	69	–	–	﹤0.01%	219
2024 Q2	$32.3K	Hold	69	–	–	0.01%	219
2024 Q1	$28.8K	Hold	69	–	–	﹤0.01%	233
2023 Q4	$28.1K	Hold	69	–	–	﹤0.01%	231
2023 Q3	$24K	Hold	69	–	–	﹤0.01%	242
2023 Q2	$24.3K	Hold	69	–	–	﹤0.01%	247
2023 Q1	$21.7K	Hold	69	–	–	﹤0.01%	262
2022 Q4	$19.9K	Hold	69	–	–	﹤0.01%	269
2022 Q3	$20K	Hold	69	–	–	﹤0.01%	263
2022 Q2	$19.4K	Hold	69	–	–	﹤0.01%	281
2022 Q1	$18K	Hold	69	–	–	﹤0.01%	290
2021 Q4	$15.2K	Buy	+69	New	+$13.4K	﹤0.01%	309
2015 Q3	–	Sell	-90	Closed	-$11.1K	–	471
2015 Q2	$11.1K	Hold	90	–	–	﹤0.01%	345
2015 Q1	$10.6K	Hold	90	–	–	﹤0.01%	367
2014 Q4	$10.7K	Hold	90	–	–	﹤0.01%	373
2014 Q3	$10.1K	Hold	90	–	–	﹤0.01%	383
2014 Q2	$8.52K	Buy	+90	New	+$6.31K	﹤0.01%	397

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Estabrook Capital Management's VRTX Position: Q1 2026 in Review

Estabrook Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 69 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #216.

Estabrook Capital Management first reported a position in VRTX in Q2 2014 and has held it in 23 quarters since. The position peaked at $33.5K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Estabrook Capital Management held 69 shares of Vertex Pharmaceuticals worth $30.8K as of Q1 2026.
Estabrook Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Estabrook Capital Management's portfolio in Q1 2026, its #216 holding.
Estabrook Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 23 quarters since.
Estabrook Capital Management's Vertex Pharmaceuticals position peaked at $33.5K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Estabrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.